ReShape Lifesciences Inc. (RSLS)
NASDAQ: RSLS · IEX Real-Time Price · USD
0.211
-0.009 (-3.95%)
Jul 19, 2024, 4:00 PM EDT - Market closed
ReShape Lifesciences Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for RSLS.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for RSLS is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 0 |
| Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 17, 2024 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $275 → $233 | Strong Buy | Maintains | $275 → $233 | +109,881.08% | May 26, 2022 |
| Maxim Group | Maxim Group | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Oct 8, 2021 |
Financial Forecast
Revenue This Year
10.19M
from 8.68M
Increased by 17.47%
Revenue Next Year
12.23M
from 10.19M
Increased by 20.00%
EPS This Year
-0.46
from -1.91
EPS Next Year
-0.37
from -0.46
Revenue Forecast
| Revenue | 2024 | 2025 |
|---|---|---|
| High | 10.5M | 12.6M |
| Avg | 10.2M | 12.2M |
| Low | 9.8M | 11.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 |
|---|---|---|
| High | 20.9% | 23.5% |
| Avg | 17.5% | 20.0% |
| Low | 12.9% | 15.3% |
EPS Forecast
| EPS | 2024 | 2025 |
|---|---|---|
| High | -0.47 | -0.38 |
| Avg | -0.46 | -0.37 |
| Low | -0.44 | -0.35 |
EPS Growth
| EPS Growth | 2024 | 2025 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.